BioNTech Expands in Asia with Biotheus Acquisition

Germany, Monday, 3 February 2025.
BioNTech has acquired Chinese biotech firm Biotheus for $800 million, enhancing its oncology strategy with rights to the BNT327 antibody platform for cancer treatment.